Could a blood-based biomarker improve relapse detection in germ cell tumours? At #ASCO26, Dr Nappi highlights data showing that circulating miR371 accurately detected recurrence in patients on active surveillance. ecancer.org/en/video/129...
Dr Lucia Nappi speaks to ecancer at ASCO 2026 about findings from the S1823/GCC.1 study, a trial evaluating circulating miR371 as a biomarker for relapse in pat
